Monopar Expands Radiopharma IP Portfolio with New Patent Filing

Monopar Therapeutics Inc., a company based in Wilmette, Illinois, and operating under the Nasdaq ticker MNPR, has announced the submission of a provisional patent for new therapeutic radiopharmaceuticals. These new compounds are built on a unique series of linkers designed to attach radioisotopes to targeting agents, such as Monopar's uPAR targeting antibody, MNPR-101.

The provisional patent covers several significant innovations:

1. **Composition of Matter:** The patent claims a family of linkers and includes Monopar's uPAR targeting agents combined with these linkers and therapeutic radioisotopes.
2. **Stability and Biodistribution:** The new linkers are engineered to improve the stability and biodistribution of Monopar's therapeutic radiopharmaceuticals.
3. **Versatility:** The innovative linker family is compatible with a wide variety of isotopes and targeting molecules, including small molecules/peptides and antibodies.

Andrew Cittadine, Monopar’s Chief Operating Officer, expressed optimism about the potential applications of these linkers. He noted that these linkers could be utilized to develop new proprietary radiopharmaceuticals aimed at well-established, high-value cancer targets of interest. This, he believes, may attract interest from other industry players, paving the way for potential licensing and collaboration opportunities.

Chandler Robinson, MD, Monopar’s Chief Executive Officer, highlighted that these novel linkers and compositions of matter are a testament to Monopar's dedication to innovation within the radiopharma sector.

Monopar Therapeutics is a clinical-stage radiopharmaceutical company committed to creating innovative cancer treatments. Their development pipeline includes MNPR-101-Zr, which is in Phase 1 for imaging advanced cancers, MNPR-101-Lu, at the Phase 1a stage for treating advanced cancers, and MNPR-101-Ac225, which is in late preclinical stages for advanced cancer treatment. Additionally, Monopar is working on early-stage programs targeting solid cancers.